A Chocolate a Day Keeps Depression Away ? Megan Brooks, Laurie Barclay Medscape, 13 / 09 /2019 https://www.medscape.org/viewarticle/917963 Clinical Context Accumulating evidence suggests that dietary factors, such as eating chocolate, may affect depressive symptoms. The potential mood-enhancing properties of chocolate may relate to its orosensory properties, psychoactive ingredients, and activation of neural reward pathways. However, only a few studies have analyzed associations between chocolate consumption and depressive symptoms, with conflicting results. The goal of this analysis was to evaluate associations between chocolate consumption and depressive symptoms in a large, representative sample of US adults enrolled in the US National Health and Nutrition Examination Survey (NHANES) between [...]
Lire la suiteMedicinal cannabis not proven in mental health, study finds Kate Kelland Reuters, Health News, October 28, 2019 LONDON (Reuters) - Evidence is weak for whether medicinal cannabis treatments can relieve mental illnesses such as anxiety, depression and psychosis, and doctors should prescribe them with great caution, researchers said on Monday. In a review of scientific studies that analyzed the impact of medicinal cannabinoids on six mental health disorders, the researchers found “a lack of evidence for their effectiveness.” Their findings have important implications for countries such as the United States, Australia, Britain and Canada, where medical cannabis is being made available for patients with certain [...]
Lire la suiteCannabinoids for the treatment of mental disorders and symptoms of mental disorders : a systematic review and meta-analysis Nicola Black, Emily Stockings, Gabrielle Campbell, Lucy T. Tran, Dino Zagic, Wayne D. Hall, Michael Farrell, Louisa Degenhardt Lancet Psychiatry, 2019 https://doi.org/10.1016/S2215-0366(19)30401-8 Summary Background : Medicinal cannabinoids, including medicinal cannabis and pharmaceutical cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have been suggested to have a therapeutic role in certain mental disorders. We analysed the available evidence to ascertain the effectiveness and safety of all types of medicinal cannabinoids in treating symptoms of various mental disorders. Methods : For this systematic review and meta-analysis [...]
Lire la suiteEffects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. Molecular Basis of Neuropsychiatric Disorders : from Bench to Bedside Sonja ELSAID, Stefan KLOIBER, Bernard Le FOLL Progress in Molecular Biology and Translational Science, 2019, 167, 25-75. doi : 10.1016/bs.pmbts.2019.06.005. Cannabis sativa (cannabis) is on of the oldest plants cultivated by men. Cannabidiol (CBD) is the major non-psychomimetic compound derived from cannabis. It has been proposed to have a therapeutic potential over a wide range of neuropsychiatric disorders. In this narrative review, we have summarized a selected number of pre-clinical and clinical studies, examining the effects of CBD in neuropsychiatric [...]
Lire la suitePsychiatric Comorbidity of Cannabis Use Disorder David Gorelick In book : "Cannabis Use Disorders", January 2019 DOI : 10.1007/978-3-319-90365-1_13 Abstract : Objective : This chapter reviews the epidemiology and treatment of cannabis use disorder (CUD) with psychiatric comorbidity. Methods : We summarize the findings of English-language epidemiological studies reporting current (past-year) comorbidity and of controlled clinical trials of treatment in which the majority of participants had diagnosed CUD and a specific comorbid disorder. Results : There is substantial CUD comorbidity among community-dwelling adults with major psychiatric disorders: 4–6% for depression, 14% for bipolar disorder, 5% for anxiety disorder, and 16% for schizophrenia. Conversely, there is substantial psychiatric [...]
Lire la suiteBIBLIOGRAPHIE : Cannabinoïdes, Dépression et Troubles de l’Humeur Docteur Christian SUEUR, GRECC, novembre 2019.
Lire la suitePlastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders Alline C. Campos, Manoela V. Fogaça, Franciele F. Scarante, Sâmia R. L. Joca, Amanda J. Sales, Felipe V. Gomes, Andreza B. Sonego, Naielly S. Rodrigues, Ismael Galve-Roperh, and Francisco S. Guimarães Frontiers in Pharmacology, 2017. doi: 10.3389/fphar.2017.00269 Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression. The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces plastic changes. [...]
Lire la suiteCannabinoids, Neurogenesis and Antidepressant Drugs : Is there a Link ? Manoela Viar Fogaça, Ismael Galve-Roperh, Francisco Silveira Guimarães and Alline Cristina Campos Current Neuropharmacology, 2013, 11, 263-275 Abstract Similar to clinically used antidepressants, cannabinoids can also regulate anxiety and depressive symptoms. Although the mechanisms of these effects are not completely understood, recent evidence suggests that changes in endocannabinoid system could be involved in some actions of antidepressants. Chronic antidepressant treatment modifies the expression of CB1 receptors and endocannabinoid (EC) content in brain regions related to mood and anxiety control. Moreover, both antidepressant and cannabinoids activate mitogen-activated protein (MAP) kinase and phosphoinositide 3- kinase(PI3 [...]
Lire la suiteUne université de Houston teste la psilocybine pour la dépression résistante aux traitements - www.NEWSWEED.fr 22 octobre 2019 Aurélien BERNARD Dans la foulée de sa décriminalisation dans quelques villes des États-Unis (Oakland et Denver notamment), la psilocybine intéresse actuellement la communauté scientifique à la recherche de preuves d’efficacité thérapeutique. Des chercheurs du Science Health Center de l’Université du Texas à Houston (UTHealth) ont annoncé qu’ils étudiaient la psilocybine pour la dépression réfractaire aux traitements. PUBLICITE L’étude est inspirée par des recherches scientifiques antérieures qui suggèrent que la psilocybine agit pour créer de nouveaux circuits mentaux. Une étude de 2012 a conclu que la substance pouvait permettre [...]
Lire la suiteEMA Panel Backs Esketamine Nasal Spray for Resistant Depression Megan Brooks Medscape Medical News, October 18, 2019 The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of esketamine nasal spray (Spravato, Janssen-Cilag) in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI) for adults with treatment-resistant major depressive disorder (TRD). Patients are considered to have TRD if they have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode. Spravato will be available as a 28 mg nasal spray solution. The safety and [...]
Lire la suite